Item 1. Notice to Convene Annual General Meeting\nOn May 12, 2020, Forward Pharma A/S (the “Company”) mailed to its shareholders a notice to convene the 2020 annual general meeting of shareholders on June 4, 2020 and accompanying documentation. The notice and accompanying documentation have been posted on the Company’s website, http://forward-pharma.com, and are being furnished as exhibits to this Report on Form 6-K.\nDate: May 12, 2020 By: /s/ Claus Bo Svendsen\nThursday 4 June 2020 at 2.00 pm (CET)\n(b) Presentation and adoption of the audited annual report;\n(c) Distribution of profit or covering of loss according to the adopted annual report;\n(d) Discharge of the board of directors and the management board;\n(e) Election of members to the board of directors;\n(f) Appointment of auditor;\n(g) Any proposals from the board of directors or shareholders; and\nThe board of directors proposes that the audited annual report for 2019 is adopted by the general meeting.\nThe board of directors proposes that the result for the accounting year 2019 be carried forward by transfer to the next financial year.\nNo proposals from the board of directors or shareholders.\nNo decisions or proposals can be adopted under item ( h).\nAll proposals under agenda items (b) – (f) may be adopted by a simple majority of votes.\nThe current share capital of the company is DKK 950,738.64, divided into 95,073,864 shares of DKK 0.01 each. Each share of DKK 0.01 carries one vote.\nThe record date is Thursday 28 May 2020 end of day (CET).\nAccess to the annual general meeting is conditional on the shareholder having requested an admission card by Friday 29 May 2020 end of day (CET).\n- returning the attached request for admission card form, duly completed and signed, by email to cbs@forward-pharma.com or by ordinary letter to Forward Pharma A/S, Østergade 24A, 1, 1100 Copenhagen K, Denmark.\nProxies shall be submitted by Wednesday 3 June 2020 end of day (CET). Voting instructions by proxy may be completed and submitted by:\n- returning the attached proxy form, duly completed and signed, by email to cbs@forward-pharma.com or by ordinary letter to Forward Pharma A/S, Østergade 24A, 1, 1100 Copenhagen K, Denmark.\nShareholders may vote by correspondence no later than Wednesday 3 June 2020 end of day (CET) by:\n- returning the attached voting by correspondence form, duly completed and signed, by email to cbs@forward-pharma.com or by ordinary letter to Forward Pharma A/S, Østergade 24A, 1, 1100 Copenhagen K, Denmark.\nDr. Moore has served on our board of directors since May 2016. Dr. Moore is a partner at East West Capital Partners since May 2008. Previously, Dr Moore was a top ranked pharmaceutical analyst at Morgan Stanley from 1991 to 2008 and was a Managing Director from 1997 to 2008 leading the firm's global healthcare equity research team. Whilst at the University of Cambridge he co-founded a medical diagnostics company called Ultra Clone with two colleagues which led to the beginnings of a 20-year career in healthcare capital markets analysis. In 1986, he was involved in setting up the Bank Invest biotechnology funds and was on its scientific advisory board. Dr. Moore was educated in Edinburgh and went to the University of Leeds where he studied Biochemistry and Microbiology. He has an M.Phil and Ph.D. from the University of Cambridge where he was also a post-doctoral research fellow. Currently, he is an active investor in biomedical companies as Chairman of Lamellar Biomedical and Oncology Ventures. In addition, he has board positions at Cycle Pharma and Braidlock.\nDr. Goesch has served on our board of directors since June 2006. He has also been the director of Rosetta Capital I, LP a secondary life sciences investor since 2002. In this function, Dr. Goesch is responsible for the management of several Rosetta Capital I, LP investments and has served as a member of the board of directors of many biopharmaceutical companies, including Enobia Ltd and Cytochroma Ltd. Dr. Goesch is also the founder and former Managing Director of TRG Invest, a Munich-based consulting business serving companies in the life science sector. Additionally, Dr. Goesch served as the General Manager for the German Speaking Countries at Biogen from 1997 to 1999, and before that was the Commercial Head of Merck KGaA's worldwide generics drug business, Merck Generics. He practiced as a physician of internal medicine at the University Hospital Hamburg-Eppendorf from 1988 to 1990, focusing on nephrology, immunology and oncology. Dr. Goesch has a Master of\nManagement from the J.L. Kellogg Graduate School of Management at Northwestern University, as well as an M.D. and Ph.D. from Heinrich Heine University Dusseldorf.\nMr. Larsen has served on our board of directors since July 2015. Mr. Larsen is currently a partner at Copenhagen-based law firm Mazanti-Andersen Korsø Jensen Law Firm LLP. Prior to January 1, 2016, Mr. Larsen was a Partner at Copenhagen-based the law firm Nielsen Nørager Law Firm LLP. Mr. Larsen serves as a trusted advisor of Danish and international private equity and venture fund managers. He has several years of experience acting as a legal adviser of biotech and life science companies. Mr. Larsen is chairman of the Danish Venture Capital and Private Equity Association's (DVCA) Legal Committee and serves as DVCA's representative on Invest Europe's Legal and Regulatory Committee. He graduated from Copenhagen University with a Master Degree in Law and holds an executive MBA from Copenhagen Business School. From 2005 to December 31, 2015 (or for those entities that were established after 2005, since their inception), Nielsen Nørager Law Firm LLP acted as our Danish legal counsel and legal counsel to the Nordic Biotech funds that currently are our shareholders, and the advisory company and the general partners of those funds. Subsequent to December 31, 2015, Mazanti-Andersen Korsø Jensen Law Firm LLP has become our Danish legal counsel and legal counsel to the Nordic Biotech funds, the advisory company and the general partners of those funds. As a former partner in Nielsen Nørager Law Firm LLP and now as a partner at Mazanti - Andersen Korsø Jensen LLP, Mr. Larsen has been and remains extensively involved in the provision of these legal services. Since 2011, Mr. Larsen has also served as a member of the board of directors of the advisory company of two of the Nordic Biotech funds that currently are our shareholders. Mr. Larsen serves on our board of directors in his individual capacity and not as a representative of any of the law firms.\nDen ordinære generalforsamling i Forward Pharma A/S afholdes\nTorsdag den 4. juni 2020, kl. 14.00\npå selskabets adresse, Østergade 24A, 1. sal, 1100 København K, Danmark.\n(a) Bestyrelsens beretning om selskabets virksomhed i det forløbne regnskabsår.\n(b) Fremlæggelse og godkendelse af revideret årsrapport.\n(c) Anvendelse af overskud eller dækning af underskud i henhold til den godkendte årsrapport.\n(d) Meddelelse af decharge til bestyrelsen og direktionen.\n(e) Valg af medlemmer til bestyrelsen.\n(f) Valg af revisor.\n(g) Eventuelle forslag fra bestyrelse og aktionærer.\nBestyrelsen foreslår, at den reviderede årsrapport for 2019 godkendes af generalforsamlingen.\nBestyrelsen foreslår, at resultatet for regnskabsåret 2019 overføres til næste år.\nBestyrelsen foreslår, at der meddeles decharge til bestyrelsen og direktionen.\nHele bestyrelsen, bestående af Florian Schönharting (formand), Duncan Charles McNaught Moore, Torsten Goesch, Grant Hellier Lawrence og Jakob Mosegaard Larsen er på valg. Bestyrelsen foreslår genvalg af alle bestyrelsesmedlemmer. Nærmere information om kandidaternes uddannelse, kompetencer og erfaring fremgår af bilag 1 (på engelsk).\nI henhold til punkt 13.1 i vedtægterne vælges selskabets revisor for ét år ad gangen. Bestyrelsen foreslår genvalg af Ernst & Young Godkendt Revisionspartnerselskab, CVR-nr. 30700228.\nIngen forslag fra bestyrelse eller aktionærer.\nIngen beslutninger eller forslag kan vedtages under punkt (h).\nAlle forslag på dagsordenen under pkt. (b) – (f) kan besluttes ved simpelt stemmeflertal.\nSelskabets nuværende aktiekapital udgør DKK 950.738,64 fordelt på 95.073.864 aktier à nominelt DKK 0,01. Hvert aktiebeløb på nominelt DKK 0,01 giver én stemme.\nRegistreringsdatoen er torsdag den 28. maj 2020 ved dagens udløb.\nEn aktionærs ret til at deltage i og stemme på den ordinære generalforsamling fastlægges på baggrund af de aktier, som aktionæren besidder på registreringsdatoen.\nDe aktier, den enkelte aktionær besidder på registreringsdatoen, opgøres på baggrund af (i) antallet af aktier registreret i selskabets ejerbog samt (ii) eventuelle meddelelser om ejerforhold, som selskabet har modtaget, men som endnu ikke er indført i ejerbogen.\nDeltagelse er betinget af, at aktionæren rettidigt har rekvireret et adgangskort.\nAdgang til den ordinære generalforsamling er betinget af, at aktionæren har rekvireret et adgangskort senest fredag den 29. maj 2020 ved dagens udløb.\nAdgangskort til den ordinære generalforsamling kan rekvireres:\n- ved at kontakte Forward Pharma A/S pr. telefon +45 33 44 42 42, eller\n- ved at returnere vedlagte bestillingsformular i udfyldt og underskrevet stand pr. e- mail til cbs@forward-pharma.com eller pr. almindelig post til Forward Pharma A/S, Østergade 24A, 1, 1100 København K, Danmark.\nStemmefuldmagter skal være indsendt senest onsdag den 3. juni 2020 ved dagens udløb. Afgivelse af stemmefuldmagt kan ske:\n- ved at returnere vedlagte fuldmagtsformular i udfyldt og underskrevet stand pr. e- mail til cbs@forward-pharma.com eller pr. almindelig post til Forward Pharma A/S, Østergade 24A, 1, 1100 København K, Danmark.\nFra aktionærer, der er forhindret i at deltage i generalforsamlingen, modtager bestyrelsen gerne en fuldmagt til at afgive de stemmer, der er tilknyttet til aktierne, for at blive bekendt med aktionærernes stillingtagen til dagsordenens forskellige punkter.\nI henhold til dansk lovgivning er en fuldmagt udstedt til bestyrelsen til brug for generalforsamlingen kun gyldig, hvis den er skriftlig.\nAktionærer kan brevstemme indtil senest onsdag den 3. juni 2020 ved dagens udløb:\n- ved at returnere vedlagte brevstemmeformular i udfyldt og underskrevet stand pr. e-mail til cbs@forward-pharma.com eller pr. almindelig post til Forward Pharma A/S, Østergade 24A, 1, 1100 København K, Danmark.\nBrevstemmer kan ikke tilbagekaldes.\nYderligere oplysninger om generalforsamlingen vil være tilgængelige på www.forward- pharma.com à ‘Investors’ til og med datoen for den ordinære generalforsamling, herunder:\n- Oversigt over det samlede antal aktier og stemmerettigheder på datoen for indkaldelsen,\n- De dokumenter, der skal fremlægges på generalforsamlingen,\n- Dagsordenen og de fuldstændige forslag samt revideret årsrapport,\n- De formularer, der skal anvendes ved stemmeafgivelse pr. fuldmagt eller skriftligt ved brevstemme.\nBestyrelsen i Forward Pharma A/S\nDr. Goesch has served on our board of directors since June 2006. He has also been the director of Rosetta Capital I, LP a secondary life sciences investor since 2002. In this function, Dr. Goesch is responsible for the management of several Rosetta Capital I, LP investments and has served as a member of the board of directors of many biopharmaceutical companies, including Enobia Ltd and Cytochroma Ltd. Dr. Goesch is also the founder and former Managing Director of TRG Invest, a Munich-based consulting business serving companies in the life science sector. Additionally, Dr. Goesch served as the General Manager for the German Speaking Countries at Biogen from 1997 to 1999, and before that was the Commercial Head of Merck KGaA's worldwide generics drug business, Merck Generics. He practiced as a physician of internal medicine at the University Hospital Hamburg-Eppendorf from 1988 to 1990, focusing on nephrology, immunology and oncology. Dr. Goesch has a Master of Management from the J.L. Kellogg Graduate School of\nManagement at Northwestern University, as well as an M.D. and Ph.D. from Heinrich Heine University Dusseldorf.\nMr. Larsen has served on our board of directors since July 2015. Mr. Larsen is currently a partner at Copenhagen-based law firm Mazanti-Andersen Korsø Jensen Law Firm LLP. Prior to January 1, 2016, Mr. Larsen was a Partner at Copenhagen-based the law firm Nielsen Nørager Law Firm LLP. Mr. Larsen serves as a trusted advisor of Danish and international private equity and venture fund managers. He has several years of experience acting as a legal adviser of biotech and life science companies. Mr. Larsen is chairman of the Danish Venture Capital and Private Equity Association's (DVCA) Legal Committee and serves as DVCA's representative on Invest Europe's Legal and Regulatory Committee. He graduated from Copenhagen University with a Master Degree in Law and holds an executive MBA from Copenhagen Business School.\nfor use at the annual general meeting in Forward Pharma A/S on Thursday 4 June 2020 at 2:00 pm (CET).\nA) ¨\tProxy is granted to a named third party (deadline Wednesday 3 June 2020 end of day (CET)):\nB) ¨\tProxy is granted to the board of directors (with a right of substitution) to vote in accordance with the board of directors’ proposals as set out in the table below (deadline Wednesday 3 June 2020 end of day (CET)).\nC) ¨\tCheck-the-box Proxy is granted to the board of directors (with a right of substitution) to vote as stated below. Please check off the boxes ”FOR”, ”AGAINST” or ”ABSTAIN” to indicate your vote (deadline Wednesday 3 June 2020 end of day (CET)).\nD) ¨\tWritten votes (voting by correspondence) are submitted as stated below. Written votes cannot be withdrawn. Please check off the boxes “FOR”, “AGAINST” or “ABSTAIN” to indicate your vote (deadline Wednesday 3 June 2020 end of day (CET)).\nAGENDA ITEMS FOR AGAINST ABSTAIN RECOMMENDATION\n(b) Adoption of the audited annual report 2019 ☐ ☐ ☐ FOR\n(c) The result for the accounting year 2019 according to the adopted annual report be carried forward by transfer to the next financial year ☐ ☐ ☐ FOR\n(d) Discharge of the board of directors and the management board ☐ ☐ ☐ FOR\n(1) Florian Schönharting ☐ ☐ FOR\n(2) Duncan Charles McNaught Moore ☐ ☐ FOR\n(3) Torsten Goesch ☐ ☐ FOR\n(4) Grant Hellier Lawrence ☐ ☐ FOR\n(5) Jakob Mosegaard Larsen ☐ ☐ FOR\n(f)\tRe-election of Ernst & Young Godkendt Revisionspartnerselskab as auditor ☐ ☐ FOR\n(g) Any proposals from the board of directors or shareholders\n(h) Any other business\nThe proxy/voting by correspondence is valid for the number of shares that the undersigned holds on the record date, Thursday 28 May 2020 end of day (CET), as calculated based on (i) the number of shares registered in the company’s register of shareholders and (ii) notifications of ownership received by the company but not yet registered in the company’s register of shareholders.\nThe dated and signed form, if used as a proxy (box A-C above) or for written votes (voting by correspondence) (box D above), must reach Forward Pharma A/S no later than Wednesday 3 June 2020 end of day (CET), either by email (cbs@forward-pharma.com) or by ordinary mail.\ntil brug ved den ordinære generalforsamling i Forward Pharma A/S torsdag den 4. juni 2020, kl. 14.00.\n(Benyt venligst BLOKBOGSTAVER)\nJeg/vi bemyndiger hermed ved fuldmagt/afgiver skriftlig stemme (brevstemme) som angivet nedenfor:\nSæt kryds i rubrik A), B), C) eller D):\nA) ¨\tFuldmagt gives til navngiven tredjemand: (senest onsdag den 3. juni 2020):\nB) ¨ Fuldmagt gives til bestyrelsen (med substitutionsret) til at stemme i overensstemmelse med bestyrelsens anbefalinger som anført nedenfor (senest onsdag den 3. juni 2020).\nC) ¨\tFuldmagt gives til bestyrelsen (med substitutionsret) til at stemme i overensstemmelse med afkrydsningen nedenfor. Sæt venligst kryds i rubrikkerne “FOR”, “IMOD” eller “UNDLAD” for at angive din stemme (senest onsdag den 3. juni 2020).\nD) ¨\tSkriftlig stemme (brevstemme) afgives som anført nedenfor. Skriftlige stemmer kan ikke tilbagekaldes. Sæt venligst kryds i rubrikkerne “FOR”, “IMOD” eller “UNDLAD” for at angive din stemme (senest onsdag den 3. juni 2020).\nDen fulde ordlyd af dagsordenen fremgår af indkaldelsen til den ordinære generalforsamling.\nHvis stemmerne knyttet til en aktionærs aktier afgives forskelligt i relation til et specifikt dagsordenspunkt, skal dette angives i oversigten nedenfor.\nPUNKTER PÅ DAGSORDENEN FOR IMOD UNDLAD BESTYRELSENS\n(a) Bestyrelsens beretning om selskabets virksomhed i det forløbne regnskabsår\n(b) Godkendelse af revideret årsrapport for 2019 ☐ ☐ ☐ FOR\n(Angiv stemmer hvis afgivet forskelligt (antal aktier)):\n(c) Resultat i henhold til den godkendte årsrapport for regnskabsåret 2019 overføres til næste år ☐ ☐ ☐ FOR\n(d) Meddelelse af decharge til bestyrelsen og direktionen ☐ ☐ ☐ FOR\n(e) Valg af medlemmer til bestyrelsen (se nedenfor)\n(f)\tGenvalg af Ernst & Young Godkendt Revisionspartnerselskab som revisor ☐ ☐ FOR\n(g) Eventuelle forslag fra bestyrelse og aktionærer\nFuldmagten gælder for alle punkter, som bliver behandlet på generalforsamlingen. Hvis der fremsættes nye forslag, herunder ændringsforslag eller forslag til valg af medlemmer til bestyrelsen eller revisor, der ikke fremgår af dagsordenen, afgiver fuldmagtshaveren stemme på dine vegne ud fra sin bedste overbevisning. Skriftlige stemmer (brevstemmer) vil blive medregnet, hvis et nyt eller ændret forslag i det væsentlige er det samme som det oprindelige.\nHvis formularen kun er dateret og underskrevet, vil den blive betragtet som en fuldmagt til bestyrelsen til at stemme i overensstemmelse med bestyrelsens anbefalinger angivet ovenfor.\nHvis formularen kun er delvist udfyldt, vil stemmerne blive afgivet i overensstemmelse med bestyrelsens anbefalinger angivet ovenfor i relation til de rubrikker , der ikke er krydset af.\nFuldmagten/brevstemmen er gyldig for det antal aktier, som undertegnede ejer ved udløbet af registreringsdatoen, torsdag den 28. maj 2020, beregnet på baggrund af (i) antallet af aktier registreret i selskabets ejerbog samt (ii) eventuelle meddelelser om ejerforhold, som selskabet har modtaget, men som endnu ikke er indført i ejerbogen.\nAnvendes den daterede og underskrevne formular som en fuldmagt (rubrikkerne A-C ovenfor) eller til at afgive skriftlig stemme (brevstemme) (rubrik D ovenfor) skal den være Forward Pharma A/S i hænde senest ved udløbet af onsdag den 3. juni 2020 enten pr. e-mail (cbs@forward-pharma.com) eller alm. post.\nThe annual general meeting in Forward Pharma A/S will be held on Thursday 4 June 2020 at 2.00 pm (CET) at the company’s premises, Østergade 24A, 1st floor, 1100 Copenhagen K, Denmark.\n- returning this request for admission card form, duly completed and signed, by email to cbs@forward-pharma.com or by ordinary letter to Forward Pharma A/S, Østergade 24A, 1, 1100 Copenhagen K, Denmark.\nDen ordinære generalforsamling i Forward Pharma A/S afholdes torsdag den 4. juni 2020, kl. 14.00 på selskabets adresse, Østergade 24A, 1. sal, 1100 København K, Danmark.\n- ved at returnere denne bestillingsformular i udfyldt og underskrevet stand pr. e-mail til cbs@forward-pharma.com eller pr. almindelig post til Forward Pharma A/S, Østergade 24A, 1, 1100 København K, Danmark.\nSæt venligst kryds i de(n) relevante rubrik(ker):\n¨ Jeg/Vi deltager i den ordinære generalforsamling og anmoder herved om et adgangskort\n¨ Jeg/Vi deltager med rådgiver:\nRådgivers navn (benyt venligst BLOKBOGSTAVER)\nYderligere oplysninger om generalforsamlingen vil være tilgængelige på www.forward- pharma.com à ‘Investors’, herunder indkaldelse til generalforsamling, dagsorden, de fuldstændige forslag og den reviderede årsrapport.\nPå vegne af: ___________________\nHvis De ønsker at give fuldmagt eller brevstemme, bedes De udfylde fuldmagts- og brevstemmeformularen. Husk venligst at datere og underskrive formularen.\nSHARES AND VOTING RIGHTS AS PER 12 MAY 2020\nOrdinary shares 950,738.64 95,073,864 95,073,864\nOutstanding shares 950,738.64 95,073,864 95,073,864\nOwn holding of shares* 0 0 0\nOutstanding shares excluding own holding of shares 950,738.64 95,073,864 95,073,864\nAKTIER OG STEMMERETTIGHEDER PR. 12. MAJ 2020\nAKTIER NOMINEL VÆRDI (DKK)\n(Á NOMINELT DKK 0,01)\nAktier 950.738,64 95.073.864 95.073.864\nUdstedte aktier 950.738,64 95.073.864 95.073.864\nEgne aktier* 0 0 0\nUdstedte aktier fratrukket egne aktier 950.738,64 95.073.864 95.073.864\n* Stemmerettigheder kan ikke udøves


Køb vin fra Powers Winery | Fri fragt | Prisgaranti - Vildmedvin\nGreg Powers, der i dag er leder og vinmager hos Powers, har lært sit metier bogstaveligt talt fra jorden op. I perioden 1982-1990, hvor Greg havde ansvaret for vinmarkerne, spillede han en aktiv rolle i overgangen til økologisk produktion, samt udformningen og opbygningen af Powers' vineri. I 1990 overtog Greg også vinifikationen af vinene. Under Gregs ledelse er Powers Winery blevet anerkendt som en "rising star" af Wine Spectator. Wine Enthusiast satte Powers på sin liste over "50 Great American Cabernet Producers".\nPowers Winery, Chardonnay 2013\nPowers Winery, Syrah 2014\nPowers Winery, Cabernet Sauvignon 2014\nPowers Sheridan Vineyards, Cabernet Sauvignon 2010


Brugte harver til salg | Nye harver til salg | Køb og salg af harver | Søgeresultat | Maskinbladet\nContainereDiverse maskiner & tilbehørGræsmaskinerGrøntsagsmaskinerGødningsmaskinerHalmhåndteringHøstmaskinerJordbearbejdningKartoffelmaskinerKornbehandlingMajsmaskinerMarkudstyrMejerimaskinerMobile staldsystemerOpvarmningRad rensereRoebehandlingSprøjterSpulereStaldmaskinerSåmaskinerTraktorerVandingsmaskinerVogne\nAlle mærker - - -AGRO - TOMAGRO-MASZAPVAgrisemAgrodanAgrokalinaAgroland AkpilAmazoneAzimBIOHARVEBednarBefaBiorotorBomfordBremerBrixCMNCarreClaydonConcept PeruginiDalboDexwal MamutDoublet-RecordEATEinbockEinböckFMAFarmetFiskarsFlemtofteFranquetFraugdeGranoGreat PlainsGregoire-BessonGüttlerHE-VAHE-VA DoubletHankmoHolsøHorschHowardIntertechJ-MaskinerJar-MetJohn DeereKRONEKellyKongskildeKronosKuhnKvernelandKvik UpKöckerlingLemkenLilla HarrieMIMads AmbyMandamMarsk StigMaschioMetangaMultivaMuratoriNamysloNew HollandNiemeyerNilaOPaLL-AGRIOmmeOrtolanPeeconPegoraroPrelaPrimoplexPræstbroPöttingerROL-EXROL/EXRabeRabewerkRolmakoSKMASScanScan-AgroScan-CombiScan-CultiSimbaSoil MasterSonnysStaltechStegstedStromStubbiesThyregodTiveTolmetTrefflerTulip MultidiscTumeUniaVamoVogel & NootVäderstadWibergWibergsZiegler\nKategori: Harver ×Fjern\nKöckerling Trio 3,5M "Arbejdsgiver søges"\nArbejdsgiver søges Ny 3,5m Köckerling Trio stubharve med stensikring. Udstyr: Betek spidser, Nivellator, Dobbelt STS valse, Langfinger efterharve og LED...\nPris: DKK 145.000,-\nAgrodan 4,6 m bred\nPris: DKK 3.500,-\nKongskilde SBA 8 M\nKverneland Turbo II 19 tands\nLilla Harrie TALLERKENHARVE SKURUPMASKINER\nPris: DKK 13.800,-\nBiorotor 4 M m. frøudstyr\nFlot bio rotor. Kanont redskab til beæmpelse af kvik, også god til at så efterafgrøder. 4m arbejdes brede. Bugser hjul for længere afstande på vej. Ring...\nPris: DKK 149.800,-\nIntertech Diskharve 4 meter med lift\nflot og velholdt 4 meters disc harve med rør pak valse den er ikke brugt ret meget der er lift i bag vi har cylinder til at lægge\nKongskilde 5 meter\nÆldre harve. Virker som den skal. Står ved Almind, Sydjylland Kontakt Peter Christensen på 26 71 13 33 eller peter@egtvedmaskinforretning.dk Se også vores...\nDoublet-Record 24 T Tallriksharv\n220cm Doublet Record tallerkenharve, i fin og god stand. Med fine tallerkener. Iorden og klar til brug.\nPris: DKK 3.600,-\nKongskilde VIBRO FLEX 13 TDS med furejævner\nPris: DKK 5.500,-\nKuhn 4003 Integra m/skiveskær\nRigtig flot såsæt.\nPris: DKK 86.700,-\nKongskilde SLA 8m\nPris: DKK 12.000,-\nGreat Plains Simba DTX300\nStår som ny\nUnia Ares XL 400\nTILBUD!!! Vejl. udsalgspris: 79.950 DKK excl. moms. Unia Ares XL 400, 4,0 m. med fast ramme. Unia Ares XL er en kompakt tallerkenharve som er det perfekte...\nPris: DKK 71.900,-\nUnia Cross Drive 400\nUnia Cross Drive 400 dybdeharve, 4,0 m. Cross Drive er en kraftig dybdekultivator til stubharvning og løsning ved pløjefri dyrkning forud for såning. Harven...\nPris: DKK 183.825,-\nKongskilde 13 tand med strigle efterharve\nViser 1 - 16 resultater af 4463


Nerdpass Jenny - Movies Galleries - Teenax Videos and Movies\nRelated searches: Nerdpass , Nerdpass Jessie , Nerdpass Misty , Nerdpass Renna , Nerdpass Monica , Nerdpass Kite , Nerdpass Innocent , Jenny Alexander , Jennifer Alexander , Nerdpass Riley , Nerdpass Katie Leigh Karson , Nerdpass Jayden , Nerdpass After School , Nerdpass Eden , See Me In Public Anal , Nerdpass Catherine , Nerd Pass , Nerdpass Kirin , Jenny , Nerdpass Ellie , Nerdpass Karina , Nerdpass Tanner , Caught By Mother , Bang Bros , Nerdpass Deal , Fucking My Stepmother , Nerdpass World , Nerdpass Cutting , Pink Visual Hd Movies , Nerdpass Renna Risi , Nerdpass Bonnie , High Quality Fuck , Nerdpass Jennifer Dark , See Me In Public , Nerdpass Charity , Nerdpass Nyla , Bangbros , Nerdpass Springbreak , Nerdpass Skate , Nerdpass Natasha\n... in Public Free Sex Video JENNY GETS FUCKED IN A PUBLIC PLACE FOR SOME COLD HARD CASH! >> This time let me introduce you to Jenny a 18 year old college student. I met her outside of some ice cream place where she was spending her last money on ...